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Abstract
Enhancer of zeste homolog2 (EZH2) is the histone lysine N-methyltransferase component of the
Polycomb repressive complex 2 (PRC2), which in conjunction with embryonic ectoderm
development (EED) and suppressor of zeste 12 homolog (SUZ12), regulates cell lineage
determination and homeostasis. Enzymatic hyperactivity has been linked to aberrant repression of
tumor suppressor genes in diverse cancers. Here, we report the development of stabilized alpha-
helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-
responsively disrupting the EZH2/EED complex and reducing EZH2 protein levels, a mechanism
distinct from that reported for small molecule EZH2 inhibitors targeting the enzyme catalytic
domain. MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and
monocyte/macrophage differentiation upon treatment with SAH-EZH2, consistent with observed
changes in expression of PRC2-regulated, lineage-specific marker genes. Thus, by dissociating the
EZH2/EED complex, we pharmacologically modulate an epigenetic “writer” and suppress PRC2-
dependent cancer cell growth.
Introduction
Epigenetic regulation dictates how distinct cell types harness the genetic code to
differentiate into diverse lineages and exert unique functions. Indeed, epigenetic
modifications of DNA and histones by a variety of protein complexes constitute
combinatorial codes of chromatin modification, amplifying the complexity of how
genetically encoded information is employed. Epigenetic information is decoded by “reader”
proteins that regulate the differential expression of genes during development and
homeostasis in conjunction with transcription factors. Two broad classes of protein
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complexes, Trithorax (trxG) and Polycomb (PcG), are responsible for the deposition of
histone marks that correlate with gene activation or repression1–3. TrxG is associated with
an ‘on state’ of gene expression characterized by methylation of Lys4 of Histone H3
(H3K4), while PcG correlated with an ‘off state’ and trimethylation of Lys27 of Histone H3
(H3K27me3). In mammals, there are two distinct PcG complexes, Polycomb repressive
complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2). PRC2 catalyzes
trimethylation of H3K27 and, at certain sites, facilitates the recruitment of PRC1 to
methylated histones to repress target genes 1,2. PRC2 is composed of three essential core
components, enhancer of zeste homolog 2 (EZH2), suppressor of zeste 12 (SUZ12) and
embryonic ectoderm development (EED). The conserved suppressor of variegation,
enhancer of zeste, trithorax (SET) domain of EZH2 contains the active site for catalysis of
H3K27 methylation4. EZH1, a close homologue of EZH2, contains a SET domain, forms an
alternative PRC2 complex with Suz12 and EED, and also catalyzes H3K27 methylation.
In addition to the established roles of the epigenetic machinery in cell homeostasis and
development, recent studies have implicated discrete protein subcomponents, such as EZH2,
in the pathogenesis of diverse cancers 5–7. EZH2 overexpression has been linked to
repression of tumor suppressor genes and derepression of genes involved in metastasis 8,9.
In certain cancers, deregulation of EZH2 expression has been associated with pathologic
alterations in microRNA levels 10,11. Somatic mutations that alter the substrate specificity
and functional activity of EZH2 have also been found in B cell non-Hodgkin’s
lymphoma 12–14. Correspondingly, reduced expression of EZH2 by shRNA or siRNA
induces proliferative arrest in cancer cell lines that overexpress EZH2 15,16. The genetic
ablation of Ezh2 alone prevents the development of a murine T cell lymphoma that results
from inactivation of Snf5, a core component of the Swi/Snf remodeling complex 17.
Collectively, these findings implicate EZH2 deregulation in the development and
maintenance of cancer, and highlight its potential as a therapeutic target.
To disable the PRC2 complex in cancer and thereby inhibit unrestrained cell proliferation,
we sought to target the interaction between EZH2 and EED, which is required for enzymatic
activity 18,19. Whereas the pharmaceutical industry has focused on the development of small
molecule inhibitors to block the methyltransferase active site of EZH2 20,21, we have
developed an alternative strategy that blocks both EZH1 and EZH2 activity by dismantling
the PRC2 complex itself through disruption of protein interactions. The essential alpha-
helical domain of EZH2 (aa 40-68) that engages EED established the basis for designing
hydrocarbon-stapled derivatives to disrupt the specific protein interaction22. Non-natural
amino acids with olefinic side chains were substituted at (i, i+4) positions within the EZH2
alpha-helical sequence, followed by ruthenium-catalyzed olefin metathesis, to yield
stabilized alpha-helix of EZH2 (SAH-EZH2) peptides. Our lead, cell permeable analog
effectively targeted EED in situ, dissociated the EZH2/EED complex, and impaired the
function of PRC2, as reflected by reduction of the H3K27me3 and EZH2 protein levels, and
increased expression of PRC2-regulated cell differentiation marker genes. In response to
SAH-EZH2 treatment, murine MLL-AF9 leukemia cells, which are PRC2-dependent,
manifested growth arrest and monocytic/macrophage differentiation, in accordance with the
phenotypic consequences of shRNA-mediated reduction of EZH2 (or EED) or genetic
ablation of Ezh2 (or Eed) 23,24. In evaluating SAH-EZH2 activity alongside the small
molecule EZH2 inhibitor GSK12621 in a series of B-cell lymphoma lines, we observed
sequence-specific anti-proliferative responses, transcriptional modulation, cellular
specificity, and a distinct mechanism of action for SAH-EZH2. Thus, we report a
pharmacologic approach to epigenetic modulation, and suppression of PRC2 function, in
particular, by targeted disruption of the EZH2/EED complex with a stapled peptide modeled
after an essential EED-interacting domain.
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Results
Synthesis and EED-Binding Activity of SAH-EZH2 Peptides
Hydrocarbon stapling has been applied to restore the natural structure of alpha-helical
binding motifs, yielding bioactive agents to dissect and target intracellular protein
interactions 25,26. To disrupt the PRC2 complex, we designed stapled peptides of variable
length based on the alpha-helical, EED-binding domain of EZH2 that comprises amino acids
40-6822. We sampled two staple positions located on the non-interacting helical surface
(Fig. 1a) and measured the binding affinity of FITC-labeled SAH-EZH2 peptides for EED
using fluorescence polarization (FP) (Fig. 1b, 1c) and co-immunoprecipitation (Fig. 1d)
assays. Both the A and B staples enhanced alpha-helicity relative to the unmodified peptide
(Supplementary Results, Supplementary Fig. 1) and the corresponding constructs showed
similar activity in both in vitro binding assays. However, significant differences emerged
upon comparison of SAH-EZH2 peptides with different length. The longest constructs,
SAH-EZH2A(40-68) and SAH-EZH2B(40-68) displayed the most potent dose-responsive
EED-binding activities, followed by SAH-EZH2A(42-68) and SAH-EZH2B(42-68). The
foreshortened SAH-EZH2A(42-64) and SAH-EZH2B(42-64) peptides lacking the IQPV
motif exhibited no appreciable engagement of recombinant EED by FP or of expressed HA-
EED by anti-FITC pull down (Fig. 1d). These data are consistent with structure-function
studies that documented the critical role of I65, P67 and V68 in the EZH2/EED
interaction 22. Thus, we identified SAH-EZH2 constructs comprising amino acids 40-68 and
42-68 as submicromolar EED binders.
In preparation for phenotypic studies in treated cells, we evaluated the cellular uptake of
SAH-EZH2 peptides in MLL-AF9 leukemia cells exposed to FITC-labeled derivatives,
followed by fluorescence analysis of electrophoresed cellular extracts (Fig. 1e). SAH-
EZH2A peptides generally displayed enhanced cellular uptake in comparison with the
corresponding constructs bearing the B-position staple, with the intermediate and shortest
peptides exhibiting the most robust dose-responsive uptake. Based upon EED-binding
potency and observed cellular penetration, SAH-EZH2A(42-68) emerged as the lead
construct for optimization and biological testing.
Suppression of H3K27 Methylation by EZH2/EED Dissociation
We previously observed that reducing net negative charge by neutralizing negatively
charged residues, such as Asp and Glu, enhances cellular uptake of stapled peptides 25,27.
Sequence comparison of EZH2 homologs indicates that Glu54 is not conserved, suggesting
that this residue is dispensable for binding to EED 22. Therefore, we mutated the non-
interacting Glu54 residue of SAH-EZH2A(42-68) to Gln (Fig. 1a and Fig. 2a). Indeed, we
observed further enhancement of cellular uptake, as measured by fluorescence scan of FITC-
SAH-treated lysates (Fig. 2b) and correlative confocal microscopy (Fig. 2c). Importantly,
the Glu54Gln mutant retained comparable in vitro binding activity to the parental stapled
peptide (Supplementary Fig. 2). To generate a negative control peptide for cellular studies,
we mutated Glu59 - a highly conserved residue among EZH2 homologs - to Gln in an effort
to disrupt the salt bridge between Arg200 of EED and Glu59 of EZH2 at the binding
interface (Fig. 1a and Fig. 2a) 22. We found this double mutant construct to manifest similar
cellular penetration (Fig. 2b) but markedly reduced in vitro EED binding activity
(Supplementary Fig. 2). Consistent with these findings, confocal microscopy documented
robust cellular uptake and nuclear localization of both SAH-EZH2A-E54Q and SAH-
EZH2A-E54Q/E59Q (hereafter referred to as SAH-EZH2and SAH-EZH2MUT, respectively)
(Supplementary Fig. 3). We next evaluated the kinetics of cellular uptake in serum-
containing media and intracellular stability (Supplementary Fig. 4). Whereas the unmodified
FITC-EZH2 peptide showed no detectable intracellular accumulation, both SAH-EZH2
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peptides and a TAT-EZH2 construct were detectable by 1 hour. Interestingly, the time
course analysis documented that both SAH-EZH2 and SAH-EZH2MUT peptides showed
progressive accumulation and persisted in full-length form, whereas the TAT-EZH2 peptide
was undetectable at 2 hours. These data indicate that hydrocarbon stapling of the EZH2
peptide sequence confers not only robust cellular uptake but also enables intracellular
persistence to both SAH-EZH2 and SAH-EZH2MUT, yet only SAH-EZH2 effectively co-
precipitated native EED from MLL-AF9 cells (Supplementary Fig. 5), consistent with the
differential EED binding activities of SAH-EZH2 and SAH-EZH2MUT (Supplementary Fig.
2)
Since the catalytic activity of PRC2 depends on the interaction between EZH2 and EED, we
explored the capacity of SAH-EZH2 to disrupt EED engagement with EZH2, and its
homolog EZH1. Of note, EZH1 shares 86% amino acid identity with the EED-binding
domain of EZH2, and is believed to form an alternate, catalytically active PRC2 complex
with EED and Suz12 28–30. In Ezh2−/− murine embryonic stem cells, EZH1 partially
compensates for loss of EZH2 and maintains H3K27me3 at a subset of developmental
genes 28. Indeed, HA-EED co-immunoprecipitated Flag-EZH1 and Flag-EZH2 upon co-
expression in sf21 cells (Supplementary Fig. 6). When incubated with these purified EZH1/
EED and EZH2/EED complexes, we observed dose-responsive dissociation of the protein
interactions for SAH-EZH2, but not for the mutant control (Fig. 2d). To determine if the
capacity of SAH-EZH2 to target and dissociate these complexes functionally impaired
PRC2 methyltransferase activity, we treated MLL-AF9 cells with SAH-EZH2 and detected
histone modification by western blot and flow cytometry. As for the small molecule EZH2
inhibitors 20,21, we employed an extended treatment course (7 days), owing to the prolonged
half-life of the H3K27me3 mark.31 Both experimental read-outs documented that SAH-
EZH2 treatment decreased H3K27me3 (Fig. 2e and Supplementary Fig. 7). Inhibition of
H3K27 methylation was also dose-responsive over a 1–10 μM range, with no H3K27me3
observed at 10 μM. The selectivity of SAH-EZH2 activity was highlighted by the inactivity
of SAH-EZH2MUT and the lack of a SAH-EZH2 effect on the H3K4, H3K9 and H3K36
methyl marks (Fig. 2f). Thus, SAH-EZH2 targeted native EED, dissociated its interactions
with EZH1 and EZH2, and selectively decreased trimethylation of H3K27.
SAH-EZH2 Arrests Proliferation of MLL-AF9 Leukemia Cells
Since MLL-AF9 cells are dependent on EZH2 and the PRC2 complex for growth 23,24, we
explored whether the biochemical activity of SAH-EZH2 translated into an anti-proliferative
effect. We treated MLL-AF9 cells for an extended incubation period and noted significantly
slowed growth by eight days for SAH-EZH2- but not mutant control-exposed cells (Fig. 3a).
These data are consistent with prior studies in which knockdown or knockout of EZH2 or
EED impaired proliferation of MLL-AF9 cells 23,24.
To investigate the mechanism of growth arrest, we stained cells with Annexin V-PE and 7-
AAD after 2, 4 and 8 day incubations with SAH-EZH2 or mutant control peptide, followed
by flow cytometric analysis. No increase in apoptotic cells was observed upon treatment
with SAH-EZH2 peptides for 8 days (Fig. 3b), whereas exposure to the chemotherapeutic
agent, camptothecin, triggered a robust apoptotic effect. Continued monitoring for apoptotic
effects through 16 days of treatment revealed only a small increase in Annexin V/7-AAD
positivity above baseline for both peptides (Supplementary Fig. 8), indicative of a sequence-
independent effect likely related to the prolonged treatment, which contrasted to the
sequence-specific anti-proliferative effect observed throughout the treatment period (Fig.
3a). We then investigated whether the observed decreased growth of MLL-AF9 cells upon
exposure to SAH-EZH2 was associated with modulation of the cell cycle using BrdU
incorporation and 7-AAD staining. Whereas flow cytometric analysis of SAH-EZH2-treated
MLL-AF9 cells showed no cell cycle effects at day 3 of treatment (data not shown), an
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increased percentage of cells in G0/G1 phase and a corresponding decrease in G2/M was
observed by day 6 (Fig. 3c and Supplementary Table 1). Compared to cells treated with the
mutant control stapled peptide, SAH-EZH2 led to an increase of cells in G0/G1 phase from
42.0% to 50.8%, and a decrease in G2/M phase from 6.7% to 3.2%. These data suggest that
the effect of SAH-EZH2 on MLL-AF9 cell proliferation resulted from reduction of the
fraction of cells in the G2/M phase. Interestingly, knockdown or genetic ablation of Ezh2
was previously reported to derepress the cell cycle inhibitory Ink4A/Arf locus 32,33.
Consistent with this finding, SAH-EZH2 treatment of MLL-AF9 cells increased p19ARF
levels, whereas cells treated with SAH-EZH2MUT, or no peptide, showed little to no
p19ARF expression (Fig. 3d). Taken together, these data indicate that the observed
proliferative arrest of cells treated with SAH-EZH2 derives from a cell cycle blockade that
is associated with increased expression of p19ARF.
SAH-EZH2 Induces Differentiation of MLL-AF9 Leukemia
As MLL-AF9 cells are EZH2-dependent and manifest differentiation blockade due to
epigenetic deregulation34, we monitored the impact of SAH-EZH2-mediated disruption of
PRC2 activity on the morphology of treated cells. We exposed MLL-AF9 cells to SAH-
EZH2 for 14 days and then replated the cells in methylcellulose with continued compound
incubation. SAH-EZH2 treatment decreased colony-forming capacity by 70% after 7 days of
plating (Fig. 4a and Supplementary Fig. 9) compared to vehicle control. No effect was
observed with SAH-EZH2MUT. Whereas vehicle- and SAH-EZH2MUT-treated cells retained
the morphology of immature leukemic blasts, exposure to SAH-EZH2 triggered myeloid
cell maturation, characterized by monocyte/macrophage morphology (Fig. 4b). Positive
staining of SAH-EZH2-treated cells with the macrophage specific antibody F4/80 confirmed
these visual findings (Fig. 4c). Whereas anti-F4/80 staining also revealed a relatively small
increase in positivity for SAH-EZH2MUT-treated cells, likely related to weak but measurable
residual EED-binding activity (Supplementary Fig. 2), we observed no impact of the mutant
peptide on cell morphology (Fig. 4b). The observed differentiation upon SAH-EZH2
treatment phenocopies the induced differentiation of MLL-AF9 cells upon shRNA
knockdown or genetic ablation of Ezh2 or Eed 23,24.
We further demonstrated the specificity of SAH-EZH2 modulation of PRC2-controlled
pathways using real time qPCR analysis of transcripts representing genes of 288 cell surface
markers (Fig. 4d). SAH-EZH2, but not the vehicle or SAH-EZH2MUT control, induced
expression of discrete monocyte and macrophage lineage-specific markers, including
Adam8, Fcer1a, and ACE (Fig. 4e), and suppressed other markers (for example, CD133)
(Fig. 4f), which are associated with hematopoietic stem cells and populations of cancer stem
cells 35–37. Downregulation of CD133 is observed upon differentiation of monocyte/
granulocyte progenitors to mature monocytes/granulocytes38. Moreover, highly enriched
MLL-AF9 leukemic stem cells (called MLL-AF9 L-GMP) express appreciably higher levels
of CD133 than more differentiated leukemic Lin+/kit− blast cells harvested from mice
(Supplementary Fig. 10).
Unique Mechanism of SAH-EZH2 anti-proliferative activity
To probe the selectivity of the anti-proliferative effects of SAH-EZH2, we evaluated
proliferative and morphologic responses in an immortalized, but non-tumorigenic, primitive
hematopoietic progenitor cell line (HPC5), and two mouse myeloid leukemia cell lines (M1
and C1492). HPC5 cells were originally derived from adult bone marrow cells immortalized
by expression of the LIM homeobox gene, lhx2 39. These cells are unique in that they
partially reconstitute hematopoiesis in lethally irradiated mice without causing leukemia. As
observed for MLL-AF9 cells, SAH-EZH2, but not its mutant derivative, inhibited the
proliferation of C1498 and M1 myeloid leukemia cells; the non-tumorigenic HPC5 cells
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showed no response (Supplementary Fig. 11). Correspondingly, the progenitor-like
morphology of HPC5 cells was unaffected by treatment with vehicle, SAH-EZH2MUT, or
SAH-EZH2 (Supplementary Fig. 11), which contrasted to the striking effect of SAH-EZH2
on differentiation of MLL-AF9 cells (Supplementary Fig. 11). In addition, SAH-EZH2 had
no effect on the viability of the non-leukemic transformed cell line 32D (Supplementary Fig.
12). These data are consistent with the previous observation that shRNA knockdown of
PRC2 components EED and Suz12 significantly decreased the proliferation of MLL-
AF9;NrasG12D cells but had minimal impact on the proliferation of the non-leukemic
transformed cell line 32D 24. Thus, we found that SAH-EZH2 treatment is selective in
inducing proliferation arrest and differentiation of leukemic hematopoietic cells.
As small molecule inhibitors that target the catalytic site of EZH2 have been described
recently20,21, we tested the activity, selectivity, and mechanism of action of SAH-EZH2
alongside an exemplary molecule, GSK126. Whereas SAH-EZH2 induced dose-responsive
reduction in H3K27me3 at a dose range that correspondingly impairs MLL-AF9 cell
viability, GSK126 was more potent in reducing H3K27me3 across the 1–10 μM dose range
(Supplementary Fig. 13), yet manifested a paradoxically weaker effect on cell viability (Fig.
5a, Supplementary Fig. 13). In the non-leukemic 32D cells, which showed no response to
SAH-EZH2 treatment, GSK126 manifested a comparable degree of cytotoxicity to that
observed for the small molecule in MLL-AF9 cells (Supplementary Fig. 12). In MDA-
MB231 (breast cancer) and DU145 (prostate cancer) lines, which have been reported to be
driven by pathologic EZH2 activity unrelated to trimethylation of H3K2740,41, SAH-EZH2
dose-responsively impaired viability, but GSK126 had no effect (Supplementary Fig. 14).
To examine potential differences in mechanism of action of SAH-EZH2 and GSK126, we
assessed the effect of each treatment on the level of EZH2 protein. We reasoned that
dissociation of the EZH2/EED complex by SAH-EZH2 may impair not only the enzymatic
activity of EZH2 activity but also impact protein stability. Indeed, we observed that SAH-
EZH2, but not GSK126, treatment led to a dose-responsive decrease in EZH2 protein levels
in MLL-AF9 cells (Fig. 5b). This result highlights a distinct mechanism of action of SAH-
EZH2.Differential effects on gene expression in MLL-AF9 cells were also observed for
SAH-EZH2 vs. GSK126 treatments. For example, changes in Adam8, ACE and CD133
levels were more pronounced upon exposure to SAH-EZH2, whereas Fcer1a was markedly
upregulated by treatment with GSK126 (Fig. 5c).
To expand the analysis to an additional cellular context, we examined the activities of SAH-
EZH2 and GSK126 in a series of B-cell lymphomas. SAH-EZH2 impaired the viability of
EZH2-mutant bearing Karpas422 (EZH2 Y641N) and Pfeiffer (EZH2 A677G) cells, with
greater potency observed in Karpas422 than Pfeiffer (Fig. 5d and Supplementary Fig. 15).
However, we observed no significant effect of SAH-EZH2 treatment on OCI-LY19 cells,
which express wild-type EZH2. The distinct effects of SAH-EZH2 on cell viability were not
related to differential peptide uptake, which was similar across cell lines in serum-containing
media (Supplementary Fig. 16). Interestingly, the relative potency of SAH-EZH2 in
Karpas422 vs. Pfeiffer cells appeared to correlate with the degree of dose-responsive
decrease in EZH2 protein levels (Supplementary Fig. 17). Treatment with GSK126 also
reduced the viability of Karpas422 and Pfeiffer cells, but at the highest dose level of 10 μM
also impaired the viability of OCI-LY19 cells (Fig. 5d), which contrasted to the lack of
activity of another EZH2 inhibitor, EPZ005687, at 10 μM in this cell line20. As observed for
MLL-AF9 cells, both SAH-EZH2 and GSK126 reduced H3K27me3 in Karpas422 cells
(Supplementary Fig. 18). Whereas GSK126 exhibited more potent inhibition of H3K27
trimethylation compared to SAH-EZH2 in Karpas422 cells in the 1–10 μM dose range
(Supplementary Fig. 18), the two compounds showed similar impairment of cell viability
(Fig. 5d). Importantly, the dose-responsive effect of SAH-EZH2 on cell viability in both
Karpas422 and MLL-AF9 cell lines correlated with the observed dose-responsive inhibition
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of H3K27 trimethylation and reduction of EZH2 protein levels over the same dose range
(Fig. 5a and 5b, Supplementary Fig. 13, 17 and 18).
Given the distinct mechanisms of action of SAH-EZH2 and GSK126, we explored whether
co-administration of the two compounds would enhance the anti-proliferative effects.
Indeed, we found that combined treatment of MLL-AF9 and Karpas422 cells with SAH-
EZH2 and GSK126 dose-responsively enhanced cellular activity compared to that of the
respective compounds administered as single agents, with evidence of synergy by Calcusyn
analysis (Combination indices [CI] of 0.11 and 0.74 for MLL-AF9 and Karpas 422,
respectively; CI<1 reflects synergy) (Fig. 5e, Supplementary Fig. 19). Taken together, these
data indicate that SAH-EZH2 manifested a unique and complementary mechanism of action
by targeting EED, dissociating the EZH2/EED complex, and reducing EZH2 protein levels.
Discussion
Alterations of chromatin landscape, including DNA methylation and histone modifications,
play critical roles in regulating gene expression. Interpretation of these epigenetic marks by
“reader” proteins is associated with gene activation or repression, depending in part on the
combination of epigenetic marks deposited by “writer” proteins. Frequent reports of genetic
lesions affecting the function of “reader” and “writer” proteins in cancers have linked
deregulation of these proteins to oncogenesis 42. EZH2 is a “writer” that catalyzes
methylation of histone H3K27 and has been implicated in a diversity of cancers. As such,
EZH2 has emerged as a high priority target for therapeutic development 5–7,43.
DZNep has been characterized as a small molecule EZH2 inhibitor that disrupts PRC2 and
manifests anti-tumor activity in a variety of cancers 44–46. Recent evidence suggests that
DZNep is a global inhibitor of histone methylation46, consistent with its pharmacologic
impairment of S-adenosylhomocysteine (S-AdoHcy) hydrolase activityand the synthesis of
S-adenosylmethionine (S-AdoMet), a global methyl group donor for diverse
methyltransferases47,48. DZNep-mediated inhibition of S-AdoMet results in global
inactivation of diverse methyltransferases. Therefore, DZNep fails to act as a selective
EZH2 antagonist. In contrast, the recently reported small molecules that directly inhibit the
catalytic site of EZH2 demonstrate more selective effects 20,21.
Here, we report an alternative strategy for selective targeting of EZH2 methyltransferase
activity by disrupting the interaction of EZH2 and EED with a hydrocarbon-stapled peptide
that mimics the alpha-helical EED binding domain of EZH2. All-hydrocarbon stapling has
been successfully applied to stabilize alpha-helical structures, enhance target binding
affinity, and confer protease resistance and membrane penetration for a diversity of
bioactive helical peptides 25,26. We found that our lead SAH-EZH2 peptide bound directly
to EED, dissociated EZH1/EED and EZH2/EED complexes, and reduced the H3K27
methyltransferase activity of the PRC2 complex. Indeed, dual targeting of PRC2-EZH1 and
PRC2-EZH2 by genetic ablation of Eed is more effective at inhibiting the oncogenic activity
of MLL-AF9 leukemia cells in vivo than eliminating Ezh2 alone 23. Correspondingly, co-
expression of EZH1 and EZH2 shRNA leads to synergistic inhibition of MLL-AF9
leukemia cell proliferation, whereas shRNA knockdown of either EZH1 or EZH2 alone
manifested only weak or no inhibitory effect in vivo 24. Thus, pharmacologic impairment of
both PRC2-EZH1 and PRC2-EZH2 is predicted to be a more effective means of silencing
PRC2 than targeting EZH2 alone.
We find that the selective blockade of PRC2 methyltransferase activity by SAH-EZH2
translates into growth arrest and differentiation of MLL-AF9 cells. The functional
consequences of this SAH-EZH2-induced epigenetic modulation were underscored by
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increased expression of macrophage-associated genes and positive staining with a
macrophage-specific antibody, findings that reflect induced monocyte/macrophage
differentiation of MLL AF9 cells. The anti-proliferative activity of SAH-EZH2 extended to
EZH2-dependent B-cell lymphomas, in which dose-responsive and peptide sequence-
dependent suppression of H3K27 trimethylation, EZH2 protein levels, and cancer cell
viability was also observed. Whereas both SAH-EZH2 and the small molecule EZH2
inhibitor GSK126 reduce H3K27 trimethylation, GSK126 targets and inhibits the catalytic
site of EZH2, whereas SAH-EZH2 dissociates the enzymatic complex and also decreases
EZH2 protein levels. These distinct mechanisms of action may account for some of the
observed differences in cellular effects and highlight the potential utility of combined
treatment. Thus, SAH-EZH2-based targeting of the PRC2 complex may represent an
alternative and complementary strategy for selectively arresting the proliferation of EZH2-
dependent human cancers.
To our knowledge, this is the first example of a selective pharmacologic strategy for
epigenetic modulation based on disruption of the intracellular binding interface between an
epigenetic “writer” and its essential cofactor. Because epigenetic “writers” bind
differentially to multiple cofactors and form diverse functional complexes to maintain
cellular homeostasis and regulate cell fate49,50, selective targeting of a pathologic
methyltransferase complex may exhibit a therapeutic window and not lead to complete ‘shut
off’ of an essential epigenetic “writer”. Indeed, we found that SAH-EZH2 arrested the
growth and induced differentiation of EZH2-dependent leukemia cells, yet had little
demonstrable effect on non-tumorigenic hematopoietic cells. These findings underscore the
sequence- and context-dependent anti-proliferative activity of SAH-EZH2.
Online Methods
Synthesis of Stabilized Alpha-Helix of EZH2 Peptides
SAH-EZH2 peptides were designed based on the EED-binding domain of EZH2, with
replacement of natural amino acids with olefinic residues at sites on the non-interacting face
of the EZH2 helix, as defined by X-ray crystallography22. Hydrocarbon stapling, peptide
purification to >95% homogeneity, quantitation, and characterization by circular dichroism
were performed as previously described in detail 25,52–54. SAH-EZH2 peptides were
synthesized on a 0.05 mmol scale with typical yields exceeding 10 mg per run. The
sequence compositions and observed masses of SAH-EZH2 peptides synthesized, purified,
and applied in this study are presented in Supplementary Table 2 and Supplementary Fig.
20.
Cell Lines and Tissue Culture
MLL-AF9 leukemia cells were generated as described in Krivtsov et al.34 and cultured in
the MLL-AF9 media, containing IMDM (Invitrogen) and supplemented with 5% fetal calf
serum (FCS), 5 ng/ml mouse recombinant IL3 (R&D systems), and 1% penicillin/
streptomycin (Invitrogen). COS7 cells (ATCC) were cultured in DMEM media (Invitrogen)
supplemented with 10% FCS and 1% penicillin/streptomycin. Sf21 cells (Invitrogen) were
cultured in Grace insect media (Invitrogen) supplemented with 10% FCS and 1% penicillin/
streptomycin.
SAH-EZH2/EED Binding Analyses
For fluorescence polarization binding analysis, C-terminal His-tagged EED (His-EED) was
expressed in Escherichia coli BL21(DE3) using 0.3 mM IPTG for 6 h at room temperature.
Bacterial pellet lysate was loaded onto a Ni-NTA column (Novagen) for purification of His-
EED. Fluorescinated stapled peptides (final concentration, 25 nM) were incubated with His-
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EED (serial dilution range, 25 nM-8 μM) at room temperature until equilibrium was reached
(~15 min). Binding activity was measured by fluorescence polarization on a Perkin-Elmer
LS50B luminescence 5 spectrophotometer. KD values were determined using GraphPad
Prism software by following equation,
y: Fluorescence polarization, X: Receptor concentration, L: Ligand concentration
AF: Minimum value of y, AB: Maximum value of y
For anti-FITC pull down-based binding assays, HA-EED was produced in Sf21 cells as
described previously 19,28. FITC-SAH-EZH2 peptides (final concentration, 50, 10, and 2
nM) were mixed with 2 μl, 0.5 μl and 0.2 μl of anti-FITC antibody (Abcam, 1 mg/ml)
respectively, and incubated with 30 μl of protein G agarose (Roche) in 400 μl binding buffer
(pH 8.0, 20 mM Tris-HCl, 150 mM NaCl, 0.3% NP40, 10% glycerol). After successive
washes, HA-EED (final concentration of 40 nM each tube) was added and incubated for 3 h,
followed by table-top centrifugation and detection of HA-EED bound to FITC-SAH-EZH2
peptides by anti-HA (Santa Cruz Biotechnology) western analysis. Detection of FITC-SAH-
EZH2 peptides was accomplished by fluorescence scan (GE Healthcare Life Sciences,
Typhoon 9200).
Cellular Uptake of SAH-EZH2 Peptides
MLL-AF9 leukemia cells were seeded in 48-well plates at densities of 2.0X105 cells per
well in 200 μl of MLL-AF9 media (5% FCS). FITC-SAH-EZH2 peptides (final
concentrations, 4, 2 and 1 μM) were added to the cells and incubated for 8 h. Cells were then
washed three times with phosphate buffer saline (PBS, Sigma) and then trypsinized (0.05%
Trypsin-EDTA, Invitrogen) at 37°C for 5 min to remove any residual peptide attached to the
cell surface. The cells were lysed with SDS loading buffer (Biorad) and brief sonication.
Lysates were electrophoresed on SDS-PAGE gels (Biorad, Criterion tris-tricine 10–20%)
and subjected to fluorescence scan (GE healthcare, Typhoon imager 9400).
Confocal Microscopy
COS7 cells were plated in 8-well CC2 ™ Chamber Slides ™(Nunc) for 1–2 days prior to
experimentation. Slides were washed twice with serum-free DMEM media (Invitrogen) and
FITC-SAH-EZH2 peptides were added in DMEM media containing 5% FCS at a final
concentration of 5 μM. After 8 h incubation, slides were washed three times with PBS and
fixed with 4% paraformaldehyde (Electron Microscopy) for 12 min. After blocking with 5%
goat serum (Vector) and staining with EED antibody (Millipore, produced in rabbit), the
slides were stained with Alexa Fluor 647 donkey anti-rabbit IgG (Invitrogen). Nuclei were
stained upon application of mounting medium containing DAPI (Vector). Confocal images
were acquired on a Zeiss LSM700 microscopy and analyzed with ZEN 2011 software
(Zeiss).
Immunoprecipitation Analyses
To assess the interaction between SAH-EZH2 peptides and native EED, MLL-AF9
leukemia cells (2×107) were cultured in 10 ml AF9 media using 10 cm dishes (BD
Biosciences) and FITC-SAH-EZH2 peptides added to final concentration of 10 μM,
followed by 8–12 h incubation. Treated cells were washed and trypsinized as above, lysed
and then incubated with 50 μl of FITC-antibody (1 mg/ml) and 100 μl of protein G agarose
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(Roche) for 3 h. The amount of EED bound to FITC-SAH-EZH2 peptides was assessed by
anti-EED western analysis (Millipore). To monitor for dissociation of native EED-EZH1/
EZH2 complexes by SAH-EZH2, Sf21 cells were co-transfected with HA-EED and FLAG-
EZH1 or FLAG-EZH2 baculovirus. EED-EZH1 and EED-EZH2 complexes were purified
by anti-FLAG agarose (Sigma) (Supplementary Fig. 6). EED-EZH1 and EED-EZH2
complexes (40 nM final concentration) were incubated with FITC-SAH-EZH2 peptides
(final concentrations, 10, 3 and 1 μM) in 200 μl binding buffer for 2 h. After successive
washes, the mixtures were incubated with anti-HA agarose (Sigma) and the level of HA-
EED-bound EZH1 and EZH2 assessed by anti-FLAG western analysis.
Analysis of Trimethylation Status
MLL-AF9 leukemia cells were seeded in 48-well plates at densities of 2×105 cells per well
in 200 μl of AF9 media (5% FCS) and then treated with SAH-EZH2 peptides (10 μM) twice
daily for 7 days. Cells were then lysed in loading buffer (Biorad) with brief sonication and
electrophoresed on SDS-PAGE gels (Thermoscientific, 4–20%). Levels of Lys4 (9751S, cell
signaling), Lys9 (5327s, cell signaling), Lys27 (07-449, Millipore) and Lys36 trimethylation
(Ab9050, Abcam) were analyzed by the corresponding trimethyl mark-specific antibodies.
For flow cytometric analysis of H3 Lys27 trimethylation, MLL-AF9 cells were treated with
SAH-EZH2 peptides (10 μM) twice daily for 7 days and then fixed in 70% cold ethanol for
overnight at −20 °C. Cells were washed twice in PBS, stained with anti-Lys27-Me3
antibody (Cell Signaling, 9733S) for 20 min and then anti-rabbit IgG Alexafluoro-647
(Invitrogen) for 20 min, followed by FACS analysis using a BD FACSCalibur.
Cell Proliferation, Apoptosis, and Cell Cycle Analyses
To monitor the effect of SAH-EZH2 peptides on cell proliferation, MLL-AF9 cells were
seeded in 48 well plates at densities of 2×105 cells per well in 150 μl of MLL-AF9 media
(5% FCS) and treated with SAH-EZH2 peptides (10 μM) twice daily. Cells were counted
every other day using a hematocytometer. To evaluate apoptosis induction, the cells were
stained with Annexin V-PE and 7-AAD after 8 or 16 days of treatment with SAH-EZH2
peptides. Camptothecin (Biovision) was used as a positive control (2 μM, 48 h). Cells were
analyzed using a BD FACScalibur and data was processed using Flowjo software. For cell
cycle analysis, cells were stained with BrdU-APC antibody and 7-AAD (BD Biosciences)
after 3 or 6 days of treatment with SAH-EZH2 peptides and 45 min of BrdU incorporation.
Cells were analyzed using a BD FACSCalibur.
Cell Viability Assays
For cells with rapid growth, such as MLL-AF9, 32D, MDA-MB231 and DU145, cells were
plated at low density (1000/well, 96 well plates), and treated in serum-containing media for
the indicated durations with twice daily SAH-EZH2 and single dose GSK126 as reported21.
Cell viability was measured by CellTiter-Glo (Promega) after 7 days of incubation. For cells
with slower growth, such as the B-cell lymphoma lines, cells were plated at higher density
(10,000 cells/well for OCI-Ly19, 5,000 cells/well for Karpas422, and 20,000 cells/well for
Pfeiffer, 96 well plates) and treated with SAH-EZH2 and GSK126 as above. Cell viability
was measured by CellTiter-Glo on days 4, 8 and 12 of treatment by cellular withdrawal and
then replacement of equivalent media volumes, with replenishment of GSK126 to maintain
treatment concentrations and incubation volumes.
High throughput microfluidic qPCR
Individual primer sets (total of 288) were pooled to a final concentration of 0.1 μM for each
primer. One ng of each RNA sample was pre-amplified using pooled primers and
CellsDirect RT/Taq enzyme (Invitrogen). Reverse transcription was performed at 50°C for
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30 min. Subsequently, in the same tube, cDNA was subjected to sequence-specific
amplification by denaturing at 95°C for 15 sec, annealing and amplification at 60°C for 5
min for 14 cycles. Pre-amplified products were diluted 5-fold prior to analysis with
Universal PCR Master Mix (Applied Biosystems), EvaGreen Binding Dye (Biotium) and
individual qPCR primers in 96×96 Dynamic Arrays on a BioMark System (Fluidigm). Ct
values were calculated using the system’s software (BioMark Real-Time PCR Analysis;
Fluidigm). Ct values of genes were normalized by subtracting Ct values of β-actin, then
normalized Ct values subtracted from 28 were used to generate the heatmap.
Cellular Differentiation Analyses
To monitor the morphology of treated cells, MLL-AF9 leukemia cells were exposed to
SAH-EZH2 peptides in MLL-AF9 media (5% FCS) for 14 days, as described above. Cells
were counted and then diluted into Methocult (STEMCELL technologies) supplemented
with 10 ng/ml IL3, 10 ng/ml IL6, 10 ng/ml SCF, 5% FCS, and 1% penicillin/streptomycin at
a density of 1000 cells/ml with continued exposure to SAH-EZH2 peptides (10 μM).
Aliquots of methocult (1 ml) were plated in 3 cm dishes (BD Biosciences) and colonies
counted after 7 day incubation. Cells were washed with PBS (Sigma), cytospun, and then
stained using modified Giemsa stain (Sigma). Morphology was assessed by light
microscopy (Nikon Eclipse E800 microscope). HPC5 cells were treated as above except that
a higher concentration of SCF (100 ng/ml) was used in the culture media. To detect
macrophage-specific cell surface marker expression, MLL-AF9 cells were treated with
SAH-EZH2 peptides for 7 d followed by successive washes in PBS and immunostaining
with Rat Anti Mouse F4/80 Antigen Alexa 647 (AbD Serotec) and PE Anti-Mouse
Neutrophils Monoclonal antibody (CEDARLANE) antibodies. Cells were analyzed by BD
FACS Calibur and data processed using Flowjo software.
Statistics
p-values were calculated using ‘R’ software with the following function:
Sample_A=c(A1, A2, A3);Sample_B=c(B1,B2,B3);t.test(Sample_A, Sample_B)$p. value
A1, A2, A3: Values of sample A
Standard Error of the Mean (s.e.m.) was calculated in accordance with the following
equation from Excel software:
s.e.m.=STDEV(a1,a2···..an−1,an)/SQRT(n)
a1,a2···..an−1,an: Values of samples
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Synthesis, EED-binding activity, and cellular penetration of SAH-EZH2 peptides
a) Design of hydrocarbon-stapled peptides to recapitulate the bioactive structure of the EED-
binding domain of EZH2. The location of stapling position ‘A’ (47–51) is marked with red
spheres and position ‘B’ (54–58) is marked with blue spheres. The alpha-helical EED-
binding domain of EZH2 is colored gold and EED is colored gray. The native methionine of
SAH-EZH2 was replaced with norleucine (‘NL’) due to the incompatibility of sulfur with
the metathesis reaction.
b) Binding affinity of SAH-EZH2 peptides for EED as measured by fluorescence
polarization assay. Data represents mean ± s.e.m. for experiments performed in triplicate.
c) Sequences and binding affinities of SAH-EZH2 peptides. CI, confidence interval
d) Anti-FITC immunoprecipitation of purified HA-EED (40 nM) upon incubation with the
indicated amounts of FITC-labeled SAH-EZH2 peptides. The results are representative of
experiments performed in duplicate. FS, Fluorescence Scan. Full gel image in
Supplementary Fig. 21
e) Cellular penetration of SAH-EZH2 peptides. Lysates of treated MLL-AF9 leukemia cells
were electrophoresed and analyzed by fluorescence scan. The results are representative of
experiments performed in duplicate. FS, Fluorescence Scan. Full gel image in
Supplementary Fig. 21
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Figure 2. Sequence-dependent dissociation of EED-EZH1/EZH2 complexes and impairment of
PRC2 activity by SAH-EZH2
a) Sequences of SAH-EZH2 and its mutants
b) Enhanced cellular penetration of the E54Q (SAH-EZH2) and E54Q/E59Q (SAH-
EZH2MUT) mutants of SAH-EZH2A(42-68), as measured by fluorescence scan of lysates
from FITC-peptide treated MLL-AF9 leukemia cells at 8 hours. The results are
representative of experiments performed in duplicate. FS, Fluorescence Scan. Full gel image
in Supplementary Fig. 21
c) Comparative cellular uptake of EZH2, SAH-EZH2A(42-68), SAH-EZH2, and SAH-
EZH2MUT peptides, as measured by confocal microscopy of FITC-peptide treated (5 μM)
COS-7 cells at 8 hours. The results are representative of experiments performed in triplicate.
d) Dissociation of HA-EED/EZH1 and HA-EED/EZH2 complexes (40 nM) by SAH-EZH2,
but not SAH-EZH2MUT, peptides at the indicated doses, as assessed by anti-HA pull-down
and EZH1/EZH2 western analysis. FS, Fluorescence Scan. Full gel image in Supplementary
Fig. 21
e) Dose-responsive suppression of H3K27 trimethylation by SAH-EZH2, administered to
cultured MLL-AF9 cells twice daily for 7 days at 1, 3, and 10 μM dosing. Full gel image in
Supplementary Fig. 21
f) Selective reduction of H3K27Me3 by SAH-EZH2, as assessed by trimethylation mark
western analysis. MLL-AF9 leukemia cells were treated with SAH-EZH2 or SAH-
EZH2MUT (10 μM) twice daily for 7 days prior to analysis.
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Figure 3. SAH-EZH2 induces cell cycle arrest and inhibits proliferation of MLL-AF9 leukemia
cells
a) SAH-EZH2 (10 μM, twice daily), but not its mutant control, inhibits the proliferation of
MLL-AF9 cells. Data represent mean ± s.e.m for independent experiments performed in
triplicate.
b) The anti-leukemic activity of SAH-EZH2 is not mediated by a pro-apoptotic effect, as
evidenced by FACS analysis and Annexin V/7-AAD staining after 8 days of treatment with
SAH-EZH2 peptides (10 μM, twice daily).
c) Cell cycle analysis of SAH-EZH2-treated (10 μM, twice daily) cells. Cells were stained
with BrdU-APC antibody and 7-AAD and analyzed by flow cytometry after 6 days of
treatment. Data represent mean ± s.e.m for independent experiments performed in duplicate
(see also Supplementary Table1).
d) SAH-EZH2, but not its mutant control, upregulates the expression of p19ARF upon
treatment of MLL-AF9 cells for 7 days (10 μM, twice daily), as assessed by western
analysis. Full gel image in Supplementary Fig. 21
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Figure 4. SAH-EZH2 induces monocyte/macrophage differentiation of MLL-AF9 leukemia cells
a) Suppression of colony-forming potential by SAH-EZH2 as compared to vehicle (water)
and SAH-EZH2MUT, p<0.02. MLL-AF9 cells were treated as described in Methods. Data
represent mean and s.e.m for independent experiments performed in duplicate.
b) Morphology of SAH-EZH2-treated MLL-AF9 leukemia cells. Whereas vehicle and SAH-
EZH2MUT -treated cells retain characteristic blastic features, SAH-EZH2-treated cells
exhibit the morphology of monocyte/macrophage differentiation.
c) Flow cytometric analysis of macrophage-specific cell surface marker expression (F4/80)
of SAH-EZH2-treated MLL-AF9 cells at 8 days (10 μM, twice daily).
d) Comparative changes in cell surface marker gene expression in MLL-AF9 cells treated
with vehicle (water), SAH-EZH2, or SAH-EZH2MUT for 8 days (10 μM, twice daily). CT-
value was processed as described in Methods and the transcripts that increased/decreased by
more than 6 fold were plotted.
e) Real Time qPCR analysis of macrophage/monocyte-specific marker expression. SAH-
EZH2-treated (10 μM, twice daily for 8 days) cells exhibit increased expression of
macrophage/monocyte specific markers. Data represent mean and s.e.m for independent
experiments performed in duplicate. pAdam8<0.11, pFcer1a<0.14, pACE< 0.29. p values were
calculated based on data comparison between SAH-EZH2 and SAH-EZH2MUT treatments.
f) Decreased CD133 expression in SAH-EZH2-treated (10 μM, twice daily for 8 days)
MLL-AF9 leukemia cells, pCD133<0.015. p values were calculated based on data
comparison between SAH-EZH2 and SAH-EZH2MUT treatments.
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Figure 5. Cell Viability Effects of SAH-EZH2 and GSK126
a) Dose-responsive effects of SAH-EZH2 and GSK126 treatment on MLL-AF9 leukemia
cell viability. Data represent mean ± s.e.m. for experiments performed in biological
triplicates and technical duplicates. Cells were treated with SAH-EZH2 (twice daily) and
GSK126 (single dose, as reported21) in serum-containing media for 7 days.
b) Effects of vehicle (water), SAH-EZH2, and GSK126 treatments on EZH2 protein level in
MLL-AF9 cells. Cells were treated with SAH-EZH2 (twice daily) and GSK126 (single dose,
and replenished at cell split due to confluency, as reported21) for 7 days. Full gel image in
Supplementary Fig. 21
c) Cell surface marker expression of MLL-AF9 cells treated with SAH-EZH2 and GSK126
as above for 8 days. Data represent mean ± s.e.m for independent experiments performed in
biological and technical duplicates.
d) Dose-responsive effects of SAH-EZH2 and GSK126 treatment on EZH2 wild-type (OCI-
LY19) and EZH2 mutant (Karpas422) B-cell lymphoma cell lines. Cells were treated with
SAH-EZH2 twice daily and GSK126 at the indicated doses for 12 days. Cells were split at
days 4, 8 and 12 for viability measurement and compounds were replenished with fresh
media to maintain concentration. Data represent mean ± s.e.m for experiments performed in
biological triplicate and technical duplicate.
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e) Effect of combination treatment at the indicated doses with SAH-EZH2 and GSK126 in
MLL-AF9 and Karpas422 cells. Calcusyn analysis51 revealed ED50 combination indices
(CI) of 0.11 and 0.74 for MLL-AF9 and Karpas422 cells, respectively (CI<1 indicates
synergy). Cells were treated twice daily with SAH-EZH2 and single dose GSK126 (as
reported21) at the indicated concentrations for 7 days. Data represent mean ± s.e.m for
experiments performed in biological triplicate.
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